ImmunityBio analyst ratings
ImmunityBio analyst ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/03/2022 | 114.48% | Jefferies | → $8 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
08/03/2022 | 114.48% | 杰富瑞集团 | → 8 美元 | 启动覆盖范围开启 | → 购买 |
ImmunityBio Questions & Answers
ImmunityBio 问题与解答
The latest price target for ImmunityBio (NASDAQ: IBRX) was reported by Jefferies on August 3, 2022. The analyst firm set a price target for $8.00 expecting IBRX to rise to within 12 months (a possible 114.48% upside). 1 analyst firms have reported ratings in the last year.
杰富瑞集团于2022年8月3日公布了ImmunityBio(纳斯达克股票代码:IBRX)的最新目标股价。该分析公司将目标股价定为8.00美元,预计IBRX将在12个月内升至12个月内(可能上涨114.48%)。1家分析公司去年公布了评级。
The latest analyst rating for ImmunityBio (NASDAQ: IBRX) was provided by Jefferies, and ImmunityBio initiated their buy rating.
杰富瑞集团提供了ImmunityBio(纳斯达克股票代码:IBRX)的最新分析师评级,ImmunityBio启动了买入评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ImmunityBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ImmunityBio was filed on August 3, 2022 so you should expect the next rating to be made available sometime around August 3, 2023.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与ImmunityBio的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。ImmunityBio的最新评级是在2022年8月3日发布的,因此您应该预计下一个评级将在2023年8月3日左右公布。
While ratings are subjective and will change, the latest ImmunityBio (IBRX) rating was a initiated with a price target of $0.00 to $8.00. The current price ImmunityBio (IBRX) is trading at is $3.73, which is within the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但最新的ImmunityBio(IBRX)评级是启动的,目标股价为0.00美元至8.00美元。ImmunityBio(IBRX)目前的交易价格为3.73美元,在分析师的预测区间内。